On June 23, 2022, Rain Therapeutics Inc. (NASDAQ: RAIN) opened at $2.89, higher 32.82% from the last session. During the day, the shares moved up to $4.39 and dropped to $2.81 before settling in for the closing price of $2.59. Price fluctuations for RAIN have ranged from $2.15 to $22.22 over the past 52 weeks.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Sponsored
Company’s average yearly earnings per share was noted -226.20% at the time writing. With a float of $15.21 million, this company’s outstanding shares have now reached $26.51 million.
The firm has a total of 44 workers. Let’s measure their productivity.
Rain Therapeutics Inc. (RAIN) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Rain Therapeutics Inc. is 15.70%, while institutional ownership is 83.60%. The most recent insider transaction that took place on Jun 01, was worth 57,250. In this transaction Chairman and CEO of this company bought 25,000 shares at a rate of $2.29, taking the stock ownership to the 2,471,627 shares. Before that another transaction happened on Jan 07, when Company’s Director bought 496,385 for $12.00, making the entire transaction worth $5,956,620. This insider now owns 1,734,960 shares in total.
Rain Therapeutics Inc. (RAIN) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 3/30/2022, the company posted -$0.66 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -$0.7) by $0.04. This company achieved a return on equity of -110.42. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.66 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -226.20% per share during the next fiscal year.
Rain Therapeutics Inc. (NASDAQ: RAIN) Trading Performance Indicators
Check out the current performance indicators for Rain Therapeutics Inc. (RAIN). In the past quarter, the stock posted a quick ratio of 9.70.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.42, a number that is poised to hit -0.66 in the next quarter and is forecasted to reach -2.21 in one year’s time.
Technical Analysis of Rain Therapeutics Inc. (RAIN)
Analysing the last 5-days average volume posted by the [Rain Therapeutics Inc., RAIN], we can find that recorded value of 0.99 million was better than the volume posted last year of 0.11 million. As of the previous 9 days, the stock’s Stochastic %D was 44.16%. Additionally, its Average True Range was 0.44.
During the past 100 days, Rain Therapeutics Inc.’s (RAIN) raw stochastic average was set at 19.25%, which indicates a significant decrease from 57.01% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 163.78% in the past 14 days, which was higher than the 127.20% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.14, while its 200-day Moving Average is $9.33. Now, the first resistance to watch is $4.28. This is followed by the second major resistance level at $5.13. The third major resistance level sits at $5.86. If the price goes on to break the first support level at $2.70, it is likely to go to the next support level at $1.97. Should the price break the second support level, the third support level stands at $1.12.
Rain Therapeutics Inc. (NASDAQ: RAIN) Key Stats
There are currently 26,510K shares outstanding in the company with a market cap of 87.34 million. Presently, the company’s annual sales total 0 K according to its annual income of -51,390 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -17,390 K.